From The Editor

  1. Reading The FDA Tea Leaves On Psychedelics 10/17/2025

    MAPS founder Rick Doblin accused the FDA of changing the goal posts after Lykos's MDMA Complete Response Letter was released, and offered insights for other psychedelic developers.

  2. Partnering To Commercialize Radiopharmaceuticals 10/9/2025

    For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new products.

  3. From Scientific Discovery To Next Generation Treatments For Obesity 7/31/2025

    Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

  4. Epic Bio's Big Swing In Epigenetic Editing 7/11/2025

    Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about epigenetic editing, working with the FDA, using AI for clinical endpoints, and more.

  5. BIO2025: Sanofi R&D, FDA's Martin Makary, Paying For New Therapies 6/20/2025

    BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.

  6. Companies To Watch: Vivani Medical 5/30/2025

    Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.

  7. Promoting A Newly Approved Indication Against Established Competitors 5/14/2025

    In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

  8. Building Uniquity Bio: Teams, Capital, And Strategy 4/30/2025

    Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.

  9. Amgen's Ian Thompson On Leadership And A Global Mindset 4/8/2025

    Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's learned from working in global markets, and key pipeline highlights.

  10. A CEO With A General Counsel's Perspective 2/28/2025

    LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.